ADJUVANT IMMUNOTHERAPY WITH ANTI-TUMOR STR. PYOGENES PREPARATION (IMMUNOPOTENTIATOR OK-432) IN UROGENITAL CARCINOMA

Abstract

尿路性器癌に対する治療法として非特異的免疫療法は, 今日, 外科的療法, 化学療法, 放射線療法に加えて非常に脚光を浴びている。われわれは, 尿路性器癌54例に対しimmunopotentiatorOK-432を皮内授与し, その担癌宿主の免疫賦活作用を検討した。検討項目は, 末梢血の白血球数, リンパ球数, 遅延型皮膚反応としてPPD skintestおよびPHAskintest, mitogenPHA, Con-A によるリンパ球幼若化率, T, B細胞測定およびIgG-FcR+T cellの測定を施行した.結果として, OK-432の皮内投与法は容易に施行でき, 発熱などの副作用もなく, 抗癌剤などの投与時に起こる白血球数減少もある程度防止できることを知った。そして, その細胞性免疫能はOK-432の投与により回復することが認められ, 宿主の延命効果に役立っているように思われた。

As a curative means for urogenital carcinoma, non-specific immunotherapy is now standing in the spotlight, in addition to such measures as surgical operation, chemotherapy and radiationtherapy. We applied an anti-tumor streptococcal pyogenes preparation (OK-432) as an adjuvant (immunopotentiator) to 54 cases principally with urogenital carcinoma through intracutaneous injection in order to examine its immunostimulative activity. I tems examined include counts of leucocyte and lymphocyte in the peripheral blood, delayed hypersensitivity skin tests to PPD and PHA, PHA and Con. A-induced blastogenesis, T. B. cell counting and IgG-FcR+ T cell. As the results, this intracutaneous injection method was found to be simple and to have caused no side reaction, further preventing leukopenia which usually occurs after chemotherapy. It was found to be effective in preserving normal cellular immunity, thus working as an agent contributing to the prolongation of life of the host.